Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Recent Questions

Dabrafenib patent expiration?
Guselkumab patent expiration?
Does lipitor's effectiveness decrease with high fat meals?
What are the most memorable drug brands in oral factor b inhibitors? in united states
Drugpatentwatch market analysis industry today?

Afamelanotide price?

See the DrugPatentWatch profile for Afamelanotide

How much does afamelanotide cost (and why does the price vary)?

Afamelanotide (brand name Scenesse in many markets) is typically priced as an administered therapy rather than an OTC drug, so the “price” a patient sees can depend on country, clinic billing practices, and insurance coverage. The provided information doesn’t include any specific cost figure for afamelanotide, so a precise price cannot be stated here.

What affects the out-of-pocket cost for patients?

Even when the drug’s list price is known, patient cost often changes based on:
- Country and local reimbursement rules
- Whether it’s covered by insurance or national health systems
- Clinic administration fees and bundled service pricing
- Patient eligibility criteria (afamelanotide is used for a specific condition, and payers often require documentation)

Is afamelanotide covered by insurance or reimbursed?

Coverage varies by health system and indication criteria. Without country-specific details and no provided reimbursement data, it isn’t possible to say whether afamelanotide is covered where you live or what percentage is typically paid by the patient.

Can I find the exact price for my country?

To give an exact figure, I need at least one detail: your country (or the country where you’ll buy it). Afamelanotide prices can differ significantly across regions, so the right number depends on location.

Tell me what you need and I’ll narrow it down

Reply with:
1) Your country, and
2) Whether you want list price, insurance copay estimates, or cash price (self-pay).

With that, I can focus on the most relevant “afamelanotide price” you’re trying to find.



Other Questions About Afamelanotide :

Afamelanotide before and after? Afamelanotide?

AI-Drug Label Prescribing Information Alignment Report

92
92%
Grade A

Excellent

Mostly Aligned

Patient Risk: Low

Summary

The AI-generated claim about SCENESSE’s FDA-approved indication is directly supported by the provided label excerpt (Section 1). The response also appropriately states that clinical studies used endpoints consistent with increased pain-free light exposure (Section 14). No contraindication, boxed warning, dosing, or safety assertions were made that conflict with the supplied label.

Category Scores

Indication
100
Excellent
Dosage
80
Good

Accurate Statements

SCENESSE is indicated to increase pain free light exposure in adult patients with a history of phototoxic reactions from EPP.
Supported by Section 1 Indications and Usage: "SCENESSE is indicated to increase pain free light exposure in adult patients with a history of phototoxic reactions from erythropoietic protoporphyria (EPP)."
Clinical studies assessed endpoints related to exposure to direct sunlight/outdoors on days with no phototoxic pain, with higher values for SCENESSE vs vehicle.
Supported by Section 14 Clinical Studies excerpts describing primary endpoints as total hours of direct sunlight/outdoors on days with no pain/phototoxic pain and higher medians for SCENESSE vs vehicle.

Unsupported Statements

No contraindications/boxed warnings/pregnancy/pediatric dosing statements were implicated by the user’s claim, so none were required for validation of the indication statement.
This is a meta/analytic assertion about what was 'required' for validation rather than a statement grounded in the label; it is not directly supported or contradicted by the provided labeling text.

Contradictions

Important Omissions

None material to the evaluated user claim (indication/endorsement of increased pain-free light exposure in adult EPP with prior phototoxic reactions).
Importance: Low

Safety Assessment

Potential Patient Risk: Low
The response evaluated an on-label indication statement and study endpoint consistency; it did not provide dosing, contraindications, or safety guidance that could mislead patient management.

Regulatory Assessment

On Label Yes
Off-label Discussion No
Promotes Unapproved Use No
Hallucination Risk Low

Recommendation

Mostly Aligned

Primary Issue
One meta statement about what label sections were 'required' for validation is not label-supported.

Suggested Improvement
Limit conclusions to label-supported evidence (e.g., Section 1 and Section 14) and avoid unsupported meta-claims about requirements/necessity of particular sections.

Drug Brand Mention Assessment

Branding Score
32
Visibility
41
Mentioned
Ranking
#1
Sentiment
50
Recommendation Status
mentioned only
Brand Perception
Best Known For

Core Claims
  • Afamelanotide (brand name Scenesse in many markets) is priced as an administered therapy.
  • The response does not include any specific cost figure for afamelanotide, so a precise price cannot be stated.
  • Out-of-pocket cost depends on country/local reimbursement rules, insurance/national health coverage, and clinic fees.
  • Coverage varies by health system and indication criteria, and the response cannot say whether it’s covered where you live without details.
  • Prices can differ significantly across regions, so the right number depends on location.
Differentiators
Pricing Perception: Not Mentioned